Racial and Ethnic Disparities in SUD Treatment

Racial and Ethnic Disparities in SUD Treatment

Racial and Ethnic Disparities in Substance Use Disorder Treatment

Accredited for 1.0 AMA PRA Category 1 Credits

Thursday, Aug. 24, 2023
12 – 1 p.m. ET



The 2023 Live Opioid CME Series is FREE for members and nonmembers,
thanks to support by a State Opioid Response Grant from:

Indiana Family and Social Services Administration
Division of Mental Health and Addiction

Registration required

Program description:

Having a meaningful conversation about the intersection of race, racism, and substance abuse first requires understanding what the term “racial health disparities” means.

Racial health disparities are defined as the “higher burden of illness, injury, disability, or mortality experienced by one (politically and socially constructed) population group relative to another.” Health disparities can also exist across other dimensions, such as age, gender identity, sexual orientation, disability status, socioeconomic status, and geographic location.

Recognizing the ways non-white Americans are disproportionately affected by these health disparities can create a pathway to greater understanding and developing solutions. Karrin Weisenthal, MD, will discuss improving initiation and access to medications for opioid use disorder with an equity lens.


At the end of this webinar, attendees will be able to:

  • Describe three ways federal policy has created racial inequities related to incarceration and treatment for substance use disorder.
  • Identify at least one method to learn more about your own implicit biases.
  • Recognize language used in the medical record that perpetuates stigma and racial stereotypes.
  • Identify ways physicians can collaborate with addiction and emergency medicine colleagues (locally or nationally) to improve equitable access to medications for opioid use disorder.



Karrin Weisenthal, MD, MHS
Emergency Medicine Physician
Boston Medical Center

About our speaker:

Dr. Weisenthal is a fellow in addiction medicine and a per diem in emergency medicine at Boston Medical Center. She also serves as a clinical instructor at the Boston University Chobanian & Avedisian School of Medicine. She received her medical degree from Yale School of Medicine and completed her residency training in emergency medicine at Boston Medical Center, serving as education chief during her final year. Dr. Weisenthal has been recognized for her academic merit and teaching abilities, receiving awards such as the David A. Frommer Award for Academic Excellence and the Senior Resident Teaching Award. Upon completion of her fellowship, she has accepted a position at Boston Medical Center/Chobanian & Avedisian School of Medicine with joint appointments in Emergency and Addiction Medicine.  

Dr. Weisenthal is an active researcher in emergency and addiction medicine. Her current research interests include improving initiation and access to medications for opioid use disorder in the emergency department (ED) with an equity lens, ensuring smooth transitions of care from the ED to outpatient settings for patients identified with a substance use disorder, and integrating a harm reduction approach into the care of patients who use drugs in the ED.

CME information

Designation Statement: The Indiana State Medical Association (ISMA) designates this live webinar for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation Statement: The Indiana State Medical Association (ISMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Disclosure Policy: In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by the ISMA must demonstrate balance, independence, objectivity, and scientific rigor. Prior to the activity, all faculty, authors, editors and planning committee members participating in an ISMA-sponsored activity are required to disclose to attendees any financial relationships with an “ineligible company” whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Disclosure Statement:  No member of the CME Planning Committee or our speaker have any relevant financial relationships with an ineligible company to disclose.

If you have questions, contact ISMA Continuing Medical Education staff at 800-257-4762 
or seminars@ismanet.org.


REGISTRATION DEADLINE: August 24, 2023, at 11:30 a.m. ET


When registering, please ensure you are taking the following steps to complete the order.

  1. Click on the “Register” button at the bottom of the event landing page.
  2. Your registration will then be “pending checkout.”  Please click on the “Proceed to Checkout” button.
  3. Your Shopping Cart will display.  Please click on the “Submit Order” button.
  4. Once you’ve successfully submitted the order, an Order Confirmation page pops up indicating that “a confirmation email is being sent to you” at the email address on file.  That confirmation email will contain the Zoom link needed to access the webinar. 

Please be sure to add ismanet.org to your White List (Safe Senders List).  This will ensure you receive our registration confirmation emails, as well as your CME certificates post-conference.

What is a whitelist sender?

An email whitelist is an approved list of senders you and your readers clearly define to ensure your email service provider (ESP) doesn't block and/or mark the content as spam.  You can add your contacts and other correspondents to the Safe Senders list to confirm you'll always receive their messages in your inbox.




8/24/2023 12:00 PM - 1:00 PM
Online registration not available.